GB1115607A — New 2,2'-dipyridyl derivatives
Assigned to Rhone Poulenc SA · Expires 1968-05-29 · 58y expired
What this patent protects
The novel compound <FORM:1115607/C2/1> is prepared by hydrogenation, in the presence of a hydrogenation catalyst, of 4,41-diamino-5,51-dinitro -2,21-dipyridyl. Intermediates isolated are 4,41-dinitramino-2,21-dipyridyl from nitration of 4,41-diamino-2,21-dipyridyl, and 4,4…
USPTO Abstract
The novel compound <FORM:1115607/C2/1> is prepared by hydrogenation, in the presence of a hydrogenation catalyst, of 4,41-diamino-5,51-dinitro -2,21-dipyridyl. Intermediates isolated are 4,41-dinitramino-2,21-dipyridyl from nitration of 4,41-diamino-2,21-dipyridyl, and 4,41-diamino - 5,51 - dinitro - 2,21 - dipyridyl by rearrangement of 4,41-dinitramino-2,21-dipyridyl under heat.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.